Head-to-head · WeighScore
Framework vs Push Health
The verdict
Push Health takes it — 56.2/100 to 51.6/100.
Push Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Push Health is a large US telehealth platform that routes brand-name GLP-1 prescriptions (Ozempic, Zepbound, Mounjaro) through a 55,000+ pharmacy network.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Framework | Push Health |
|---|---|---|
| WeighScore | 51.6/100 | 56.2/100 |
| Grade | C | C |
| Scorecard rank | #485 | #419 |
| Semaglutide | Not disclosed | $950/mo (brand-name) |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #485 · C
Strengths
- The compounding pharmacy partner is named, which most of this field does not do
- Treatment selection is doctor-guided rather than a fixed product menu
- US-licensed clinicians and a 503A pharmacy pathway
Where it loses points
- No monthly medication price is published: the tirzepatide and semaglutide pages carry no price at all, and the homepage advertises a per-week figure for 'GLP-1s' generally rather than a rate for either drug
- The only drug-specific prices anywhere on the site sit on a legacy page — semaglutide at $349 per three months and tirzepatide at $549 per three months
- A '$75/month with 3-month package' figure is footnoted as a promotion for new GLP-1 users only
- Different landing pages advertise different per-week rates, $25 on one and $19 on another
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #419 · C
Strengths
- Brand-name-only GLP-1 distribution (Ozempic, Zepbound, Mounjaro)
- 55,000+ pharmacy network per competitor sources
- LegitScript certified per competitor sources
- Listed in both competitor directories
Where it loses points
- Brand-name-only — no compounded option
- Stub entry — exact pricing, insurance coordination, and clinician workflow need YMYL verification
- Confidence LOW until verified
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.